加载中
NASDAQHealthcareBiotechnology
最新数据
US$4.865
−US$0.405 · -7.69%
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
常规交易时段
US$4.865
−US$0.405 · -7.69%
盘中时间采用ET。市场数据可能有所延迟。
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
日内区间
当前US$4.865
52周区间
当前US$4.865
盘中时间采用ET。市场数据可能有所延迟。
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
日内区间
当前US$4.865
52周区间
当前US$4.865
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | — | 88.17万 USD |
| 销货成本 | — | 60万 USD | — | 148.79万 USD | 163.92万 USD |
| 毛利 | — | −60万 USD | — | −148.79万 USD | −75.75万 USD |
| 研究与开发 | 7009.5万 USD | 3222.2万 USD | 3116.8万 USD | 1613.68万 USD | 3644.53万 USD |
| 销售、一般及管理费用 | 1521.5万 USD | 1649.9万 USD | 1391万 USD | 1869.86万 USD | 2042.54万 USD |
| 营业费用 | 8531万 USD | 4812.1万 USD | 4507.8万 USD | 3334.76万 USD | 5523.15万 USD |
| 利息收入 | 553万 USD | 631.1万 USD | — | — | — |
| 利息支出 | — | 187.2万 USD | 292.4万 USD | 213.21万 USD | 183.05万 USD |
| 折旧和摊销 | 23.3万 USD | 58.8万 USD | 64.1万 USD | 148.79万 USD | 163.92万 USD |
| 营业利润 | −8531万 USD | −4872.1万 USD | −4507.8万 USD | −3483.54万 USD | −5598.9万 USD |
| 净利润 | −7853.7万 USD | −4020.9万 USD | −4460.4万 USD | −5583.32万 USD | −4555.26万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$33.67
上涨空间 592.09%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2023年2月14日 | 1:30 | — | — |
已生效 2023年2月14日
1:30
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI582.13万0.00%2.3万亿 USD0.03%US$381.34-0.06%
iShares Russell 2000 ETFIWM225.12万0.00%787.4亿 USD0.19%US$276.98-0.33%
Vanguard Extended Market ETFVXF215.63万0.00%954亿 USD0.05%US$232.71-0.35%
Vanguard Russell 2000 ETFVTWO103.31万0.01%180亿 USD0.06%US$111.87-0.36%
iShares Russell 2000 Value ETFIWN82.27万0.01%137.49亿 USD0.24%US$210.97-0.06%
Dimensional - US Small Cap ETFDFAS53.79万0.00%338.04亿 USD0.31%US$78.27+0.13%
Fidelity Enhanced Small Cap ETFFESM48.37万0.01%64.1亿 USD0.28%US$45.155-0.19%
iShares Micro-Cap ETFIWC28.42万0.02%13.17亿 USD0.60%US$180.27-0.77%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOiShares Russell 2000 Value ETFIWNDimensional - US Small Cap ETFDFASFidelity Enhanced Small Cap ETFFESMiShares Micro-Cap ETFIWCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
